A Clinical Safety and Efficacy Comparison of NEVANAC 0.1% to Vehicle Following Cataract Surgery in Diabetic Retinopathy Patients - MIZAR.

Trial Profile

A Clinical Safety and Efficacy Comparison of NEVANAC 0.1% to Vehicle Following Cataract Surgery in Diabetic Retinopathy Patients - MIZAR.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Nepafenac (Primary)
  • Indications Diabetic complications; Diabetic macular oedema
  • Focus Registrational; Therapeutic Use
  • Acronyms MIZAR
  • Sponsors Alcon
  • Most Recent Events

    • 01 Apr 2013 Status changed from recruiting to discontinued as reported by Clinical Trials Registry - India.
    • 09 Jun 2012 Additional location Germany added as reported by European Clinical Trials Database record.
    • 17 May 2012 Actual number of patients changed from 166 to 175 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top